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DEVELOPING MENACALC: AN ASSAY TO PREDICT RISK  
OF BREAST CANCER TUMOR METASTASIS THROUGH QUANTIFICATION 
OF MENA PROTEIN ISOFORMS 
MICHELLE DIVELBISS 
ABSTRACT 
Metastasis is the leading cause of poor prognosis for individuals diagnosed with 
cancer. Breast cancer is particularly prevalent with 1 in 10 women receiving a breast 
cancer diagnosis in her lifetime. There are various types of breast cancers that are 
distinguished by molecular subtype as defined by specific biomarker expression profiles:  
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER2). The subtypes defined by the varying expression of these receptors 
respond differently to cancer treatments. For example, luminal A ([ER/PR+] HER2- 
KI67-) responds well to endocrine therapy and patients generally have a good prognosis, 
whereas triple negative breast cancer (TNBC) ([ER/PR-] HER2- basal marker+) has no 
specific targeted treatment available and the prognosis is usually poor. Patients with the 
HER2 subtype often develop resistance to the treatment specific to the breast cancer 
molecular subtype. Since 90% of all cancer-related deaths are due to metastatic disease, 
effectively treating all of these types of breast cancers before metastasis is an important 
factor in achieving a more positive outcome, 
 In order for metastasis to occur, a tumor cell must have the ability to mobilize, 
intravasate into the vasculature, and then extravasate and proliferate into a tumor at a 
distant site. Numerous biological and environmental factors must facilitate each of these 
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steps in order for metastasis to occur. One biomarker of metastasis is a tumor 
microenvironment of metastasis (TMEM). A TMEM is the physical apposition of a 
Mena-expressing tumor cell, a macrophage (a type of white blood cell), and an 
endothelial cell (a blood vessel cell). Each TMEM component plays a key role in breast 
cancer biology. The automated clinical assay MetaSite BreastTM was developed by 
MetaStat, Inc. to quantify TMEMs. The MetaSiteTM score directly correlates with risk of 
developing metastasis.  
The Mena protein is involved in cell motility and expressed isoforms can either 
promote metastasis (for example, MenaINV), or protect and prevent metastasis (for 
example, Mena11a). These isoforms are not expressed in a binary manner and studies 
have shown that the ratio of MenaINV to Mena11a can give insight into the pro-
metastatic/anti-metastatic biology of the cell. To indirectly measure the amount of 
MenaINV, the Z-score of Mena11a is subtracted from the Z-score of pan-Mena (all Mena 
isoforms), yielding a theoretical maximum amount of MenaINV, called Menacalc. This 
process is performed by quantitative analysis of multiplexed immunofluorescence 
staining through the MenaCalcTM assay developed by MetaStat, Inc. 
The results of this study demonstrated that MenaCalcTM is a high-performing, 
high-throughput assay that was clinically validated under CLIA-approved protocol in 
January 2016. The assay surpassed all benchmark goals for precision and performance. 
For both day-to-day and run-to-run operations, precision and reproducibility were 
analyzed using Pearson’s R and slope. The day-to-day reproducibility yielded Pearson’s 
R values of 0.879 and 0.853 comparing Day 1 vs. Day 2 and Day 2 vs. Day 3, 
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respectively.  The slopes for the same comparisons were 0.985 and 0.982, respectively. 
The analysis of run-to-run precision had Pearson’s R values of 0.999 and 0.994 
comparing Day 1 vs. Day 2 and Day 2 vs. Day 3, respectively. The slopes were 0.999 for 
both comparisons. The development of such an assay brings new elements of precision 
and reproducibility to the current market of breast cancer biomarker tests. 
Statistical analysis revealed a wide range of MenaCalcTM scores that were 
independent of total Mena expression. Individual images showed a range of MenaCalcTM 
values from a low of only 2.9% of cells with a high MenaCalcTM score to a high of 97.4% 
of cells with a high MenaCalcTM score. Regions of high MenaCalcTM scores correlated 
with areas of invasive tumor.  
Preliminary data assessing the synergistic use of both the MetaSite BreastTM and 
the MenaCalcTM assays were promising. These data suggests that both physical 
MetaSiteTM structures and protein expression levels can be used to more thoroughly 
understand the biology of breast cancer and the path to metastasis. Three clusters of 
combined MetaSiteTM/MenaCalcTM scores were observed: MetaSiteTM low/MenaCalcTM 
low, MetaSiteTM low/MenaCalcTM high, MetaSiteTM high/MenaCalcTM high. Because a 
MetaSiteTM High/MenaCalcTM Low score combination was not observed, a high 
MenaCalcTM score may be necessary for TMEM formation. Studies are ongoing to 
further evaluate the synergy of the MetaSite BreastTM and the MenaCalcTM in order to 
bring more power to the assessment of metastatic risk.   
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INTRODUCTION 
 Every day approximately 1,500 people in the United States die from cancer (Roh-
Johnson et al., 2014). Breast cancer is the leading cause of death among women in 
industrialized countries, such as the United Kingdom and the United States, where 
approximately 1 in 10 women receive a breast cancer diagnosis. 
There are a variety of risk factors for developing breast cancer, most notably age, 
family history, and hormone levels. A woman’s risk of breast cancer increases as she 
ages. At age 30, a woman’s risk of developing breast cancer in the next 10 years is 
0.44%; at age 50, the risk increases to 2.73%; at age 70, the risk increases again to 
4.14%. Overall, a woman’s lifetime risk of developing breast cancer is 13.22% (Hunt, 
2008).  
Women with a first-degree relative (mother, sister, or daughter) diagnosed with 
breast cancer face a 1.8-fold greater relative risk than the general population. This 
relative risk increases to a 4.0-5.4-fold greater risk if the first-degree relative is post-
menopausal at the time of a bilateral breast cancer diagnosis (Hunt, 2008). “Early 
menarche (before 12 years of age), late menopause (at or after 55 years of age), late age 
at first full-term pregnancy (35 years or older), and nulliparity all increase a woman’s risk 
of breast cancer by affecting endogenous reproductive hormones” (Hunt, 2008). 
Exogenous hormones can also contribute to risk. Studies on the effects of 
hormonal birth control have mixed results. Some studies have shown that birth control 
can slightly increase a woman’s risk of breast cancer, whereas others have shown no 
increased lifetime risk (Chlebowski et al., 2003). However, women who take exogenous 
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hormones as post-menopausal hormone replacement therapy have an increased risk of 
developing breast cancer. A trial conducted by Women’s Health Initiative found a 24% 
greater risk associated with estrogen plus progesterone therapy (Chlebowski et al., 2003).  
Nevertheless, therapies have a wide range of associated risks and the effectiveness of a 
given treatment varies among types of breast cancer. 
 
Breast Cancer Molecular Subtypes 
Breast cancer is the blanket term for a variety of heterogeneous types of tumor 
that are distinguishable by various biomarkers. These markers include estrogen receptor 
(ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), 
and KI67 nuclear protein, which are further identified by pathological markers such as 
nodal status, tumor size, and histological type (i.e., ductal versus lobular) (Dai et al., 
2015). These markers are grouped into breast cancer molecular subtypes based on their 
expression and/or lack of expression. The subtypes are stratified by prognosis and ideal 
therapeutic treatment. Selected intrinsic subtypes are shown in Table 1. 
Different diagnostic tests are used to identify a patient’s individual breast cancer 
molecular subtype. The presence or absence of estrogen receptors, progesterone receptors 
and KI67 is revealed using immunohistochemistry (IHC) and the results determine the 
feasibility of endocrine therapy. Although widely used, current IHC assays are only 
moderately predictive and precision and performance vary widely. Different laboratories 
have processes for fixation, antigen retrieval, and staining that vary slightly. In addition, 
different laboratory personnel running the same test can cause variances within a single 
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laboratory. One study analyzed the results of 200 different labs which were each given 
the same three tumors and “false-negative rates were as high as 30%-60% (depending on 
the cutoff) in the low ER-positive case” (Pusztai, 2006). This same study found that the 
duration of formalin fixation could change the degree to which estrogen receptors were 
detected with increased fixation time correlating with increasing IHC scores.  
 
Subtype IHC Status Outcome Prevalence Treatment 
Luminal A [ER/PR+] HER2-KI67- Good 23.7% Endocrine therapy 
Luminal B [ER/PR+] HER2-KI67+ 
[ER/PR+] HER2+KI67+ 
Intermediate 
Poor 
38.8% 
14% 
Endocrine therapy 
Endocrine therapy 
HER2  [ER/PR-] HER2+ Poor 11.2% Trastuzumab or 
anit-HER2 therapy 
TNBC [ER/PR-] HER2-, basal+ Poor 12.3% Chemotherapy 
Table 1. Selection of the most common breast cancer molecular subtypes, IHC 
status, outcome, prevalence, and primary treatment. Significance is discussed in the 
text. ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; IHC = 
immunohistochemistry; KI67 = nuclear protein; PR = progesterone receptor. Adapted 
from Dai et al. (2015) and Schnitt (2010). 	  
HER2 molecular subtypes are determined by measuring the levels of HER2 
proteins in the cell membrane with IHC and by analyzing HER2/neu gene amplification 
with fluorescence in situ hybridization (FISH) (Perez et al., 2002). The testing methods 
for HER2 also vary in their concordance, especially among lower scoring samples. 
Biomarkers have proven to be important prognostic tools; however, without 
precision, their potential to inform treatment and predict prognosis is vastly underutilized. 
To improve patient outcome, highly precise and reproducible assays are necessary. One 
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such development is the MenaCalcTM assay (MetaStat Inc., Boston, Massachusetts, 
USA), which aims to predict patient outcome and provide prognostic utility in a reliable 
manner.  
Tumors that are ER/PR+ proliferate in the presence of estrogen and progesterone. 
They generally respond well to endocrine therapy, which acts on the estrogen and 
progesterone receptors. Tamoxifen and aromatase inhibitors are two such therapies that 
work to inhibit the hormones (by way of the hormone precursors). Patients with the 
luminal A molecular subtype have a good prognosis, whereas patients with the luminal B 
subtype have a poor to intermediate prognosis based on the KI67 status and the HER2 
status. KI67 is a marker for cell proliferation and its presence accounts for the difference 
in outcomes for patients with [ER/PR+] HER2-KI67- (luminal A) and [ER/PR+] HER2-
KI67+ (luminal B) subtypes. With other biomarkers being the same, a patient with tumor 
cells expressing KI67 has more actively dividing cells which contribute to a worse 
prognosis (Ahmad, 2013).  
A second luminal B subtype, [ER/PR+] HER2+KI67+, shows poor prognosis 
because of a variety of pro-tumor markers. HER2 encodes a gene that is part of the 
epidermal growth factor receptor family (EGFR) and is often amplified along with the 
GRB7 gene, a proto-oncogene. Since its development over a decade ago, trastuzumab 
(Herceptin) has significantly reduced relapse rates among patients with HER2-expressing 
breast cancer. However, many patients either have de novo resistance to trastuzumab or 
develop resistance within a year. Between 66% and 88% of patients with HER2-positive 
breast cancer have some form of trastuzumab resistance (Chung, Cui, Audeh, & Giuliano, 
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2013). These findings have stimulated research into alternative therapies such as “a 
small-molecular tyrosine kinase inhibitor, lapatinib (Tykerb); a monoclonal antibody that 
inhibits HER dimerization, pertuzumab (Perjeta); and a conjugate of trastuzumab with a 
cytotoxic as a form of targeted delivery, TDM-1” (Davidson, 2013). These developments 
are helping to improve the prognosis for patients diagnosed with HER2-positive breast 
cancer.  
Triple-negative breast cancer (TNBC), as indicated by [ER/PR-] HER2-KI67-, 
does not have any ER, PR, HER2, or KI67 markers. These tumors often express proteins 
such as basal cytokeratins and EGFR. TNBC requires combination therapy to treat and 
has a poor prognosis for the first 3-5 years after diagnosis. However, TNBC has a better 
long-term prognosis than hormone-positive breast cancers (Hudis & Gianni, 2011).  
 
Components of Metastasis  
Tumor cell metastasis is the leading cause of poor prognosis in patients diagnosed 
with breast cancer. The fight to improve patient outcome after a cancer diagnosis lies in 
preventing metastasis or in predicting metastasis and treating aggressively. Just as 
invasive cancer requires a series of genetic and biological changes to occur, metastasis 
also requires a series of events, known as the metastatic cascade (Kaiser, Nasir, & Nasir, 
2008). First, the invasive tumor cell must be mobile; second, the cell must intravasate 
into the vasculature; and third, the cell must extravasate and proliferate in a secondary 
site. Each step in the metastatic cascade requires key components in order for a tumor cell 
to successfully metastasize. The presence of various biological or physical markers in 
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tumor tissue can indicate metastasis and therefore poor prognosis. A tumor 
microenvironment of metastasis (TMEM) is a physical structure composed of a Mena-
expressing tumor cell, a perivascular macrophage, and an endothelial cell all in direct 
apposition to one another. It is when these three components are touching that the tumor 
has both the opportunity and the ability to metastasize. It has been demonstrated that 
tumors with higher TMEM density have a greater chance of developing metastatic 
disease. (Rohan et al., 2014) 
 
The Mena Protein 
The Mena (mammalian Ena) protein is a member of the Ena/vasodilator-
stimulated phosphoprotein (VASP) protein family that is involved in cell motility; 
specifically, the polymerization of F-actin allows the cell to chemotax toward or away 
from a stimulus (Gurzu, Ciortea, Ember, & Jung, 2013). “Ena/VASP proteins share a 
conserved domain structure including the N-terminal EVH1 (Ena/VASP Homology 1) 
domain, that plays an essential role in intracellular protein localization”(Goswami et al., 
2009). 
As shown in Figure 1, there are two main Mena protein isoforms of note: Mena 
invasive (MenaINV) and Mena11a. The MenaINV exon is a sequence of 19 amino acids 
located adjacent to the N-terminal Ena/VASP Homology 1 (EVH1) domain, and the 
Mena11a exon is a sequence of 21 amino acids located on the C-terminal side of the F-
actin binding domain (FAB).  
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Figure 1. Domain organization of the Mena protein and the alternatively spliced 
exons. Based on epigenetic expression, the alternatively spliced Mena mRNA transcript 
can be either prometastatic (MenaINV exon is expressed) or protective (Mena11a exon is 
expressed). Adapted from Goswami et al. (2009). 	  
Research suggests that (1) the upregulation of MenaINV and simultaneous 
downregulation of Mena11a indicates invasive tumor cells and (2) the downregulation of 
MenaINV and simultaneous upregulation of Mena11a indicate non-invasive tumor cells 
and may be protective against metastasis (Agarwal et al., 2012). Mouse model studies 
showed an 8.7-fold increase in total Mena expression (pan-Mena) and a 7.5-fold increase 
in MenaINV expression in metastatic tumor cells compared with non-metastatic tumor 
cells (Roussos et al., 2011). These studies suggest that Mena11a is expressed in healthy 
tissue and is upregulated in cancer cells. However, because Mena11a expression is not 
sufficient to promote invasive metastasis by itself, there must be other pro-metastatic 
factors present. Conversely, MenaINV can promote metastasis in the absence of outside 
pro-metastatic factors (Philippar et al., 2008). Mena11a is exclusively expressed in cells 
that are morphologically epithelial in nature, but it is not expressed after the cell 
undergoes an epithelial to mesenchymal transition.  
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Epithelial to Mesenchymal Transition and E-Cadherin 
The epithelial to mesenchymal transition (EMT) is a biologically normal process 
that occurs during embryogenesis and other processes (such as organ development) in 
which cells differentiate and migrate under the direction of chemotactic factors. It 
“allows a polarized epithelial cell…to undergo multiple biochemical changes that enable 
it to assume a mesenchymal cell phenotype, which includes enhanced migratory capacity, 
invasiveness, [and] elevated resistance to apoptosis…” (Kalluri & Weinberg, 2009). This 
transition is also an important step in the metastatic cascade. In the absence of EMT-
promoting signals, cells can revert back to the epithelial form as secondary tumors at 
distant locations after metastasis by means of a mesenchymal to epithelial transition 
(MET) (Hurst & Welch, 2011).  
An indication of non-invasive tumor cells is the presence of E-cadherin (epithelial 
cadherin), a protein present in adherens junctions between cells. Cell-to-cell adherens 
junctions are attached to the interior actin network of the cell. The disruption of adherens 
junctions is one step that facilitates susceptibility to an endothelial to mesenchymal 
transition. The downregulation of E-cadherin correlates with Mena-positive/Mena11a-
negative tumor cell expression. Because of this correlation, the presence of E-cadherin 
may be one factor that is protective against metastasis. Further, Mena-positive/Mena11a-
negative tumor cells were found to have a mesenchymal phenotype, strengthening the 
relationship between Mena expression, E-cadherin, and epithelial to mesenchymal 
transition (Di Modugno et al., 2012).  
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Figure 2. The presence of E-cadherin with respect to MenaINV and TMEM. The 
graphs show the association of E-cadherin staining intensity with the MenaINV and 
TMEM scores. (A) Low MenaINV and low TMEM scores indicate non-invasive tumor 
cells which have high staining intensity, and therefore high density of E-cadherin 
proteins. (B) High MenaINV and high TMEM scores indicate invasive tumor cells which 
have low staining intensity and low presence of E-cadherin proteins. (C) Micrographs 
illustrate the staining intensity scores (0 = none; 3 = strong) for the presence of E-
cadherin. Adapted from Pignatelli et al. (2014). 	  
E-cadherin has been shown to have a negative correlation with both MenaINV 
expression and TMEM density (Figure 2). This suggests that there are many factors that 
contribute to and can help indicate tumor cell metastasis. Several studies have found that 
“TMEM counts are associated with risk of metastasis in breast cancer patients 
independently of lymph node, ER/PR or HER2 status” (Roussos et al., 2011). Studies 
have also shown that MenaINV-expressing tumor cells have increased sensitivity to 
epidermal growth factor (EGF), which is produced by tumor-associated macrophages. 
	  10 
Moreover, it has been proposed that MenaINV-expressing tumor cells are involved in the 
creation of TMEMs, perhaps through paracrine signaling with macrophages (Roussos et 
al., 2011). 
 
Macrophages and Chemotactic Factors 
Macrophages have diverse functions that are tightly regulated throughout the 
body. They have roles in angiogenesis, inflammatory response, cancer initiation and 
promotion, and many other activities. Macrophages interact with their environment 
through a variety of signals that influence macrophage function, the function of nearby 
cells, and the microenvironment in which they reside (Sullivan & Pixley, 2014).   
One such regulating factor is “Colony-stimulating factor-1 (CSF-1), also known 
as macrophage-colony stimulating factor (M-CSF), [which] is the primary growth factor 
regulating survival, proliferation and differentiation of macrophages” (Sullivan & Pixley, 
2014). Tumor cells secrete CSF-1 to recruit macrophages and overexpression of CSF-1 at 
the invasive front of the tumor promotes and maintains a population of tumor-associated 
macrophages. In a 2002 study by Lin, Gouon-Evans, Nguyen, and Pollard, it was shown 
that high levels of CSF-1, particularly at the tumor site itself, correlate with poor 
prognosis. Using transgenic mouse models, these researchers noted that decreased levels 
of CSF-1 and the complete lack of CSF-1 lead to a slower and delayed tumor progression 
and metastasis. The same study analyzed how locally expressed CSF-1 affects tumors 
and found that tumor progression correlates with increased levels of localized CSF-1 (Lin 
et al., 2002).  
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Macrophages secrete a variety of chemotactic factors and one of marked 
importance is epidermal growth factor (EGF). EGF regulates cell motility by adhesion 
and protrusion and plays a role in cross-talk between macrophages and tumor cells 
through EGF and CSF-1 signaling. In a positive feedback loop, tumor cells secrete CSF-1 
to recruit macrophages, the presence of CSF-1 induces macrophages to secrete more 
EGF, and the increased secretion of EGF promotes increased CSF-1 secretion by tumor 
cells. EGF induces the formation of long tumor cell protrusions, called invadopodia, that 
give the tumor cell one physically necessary feature for metastasis. Tumor cell 
invadopodia contain a network of actin and are specialized to degrade the extracellular 
matrix (ECM) (Wells, 2006). 
Another pro-invasion factor is vascular endothelial growth factor (VEGF), which 
is upregulated in breast cancer. VEGF plays a variety of roles that include stimulating 
migration in macrophages, forming new blood vessels, and regulating blood vessel 
permeability. Increased expression of VEGF corresponds to increased levels of 
macrophages at the tumor site. Aggressive tumors have significant areas of oxygen 
depletion resulting from a lack of vasculature. Hypoxia promotes the production of 
VEGF, which triggers both angiogenesis and macrophage infiltration. Through various 
signaling pathways, macrophages reinforce the angiogenic process and the overall growth 
of tumors (Leek et al., 2000).  
Secreted chemotactic factors such as CSF-1, EGF, and VEGF work together to 
provide a partial ability for tumor cells to break through the basement membrane and to 
intravasate into the vasculature.  
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Endothelial Cells: Intravasation and Extravasation 
In order for tumor cells to metastasize, they must move from the primary tumor 
site through the ECM to a blood vessel. An illustrated model of the steps of metastasis—
invasion, intravasation, extravasation, and proliferation at a distant site—is shown in 
Figure 3 (Reymond, d’Água, & Ridley, 2013).  
Through the positive feedback paracrine loop of CSF-1 and EGF, the tumor cells 
acquire a greater ability to remodel the surrounding extracellular matrix. Studies have 
shown that in the absence of CSF-1, tumor growth is not affected, but the ability of the 
tumor to progress towards metastasis is greatly reduced or even eliminated (Lin et al., 
2002). This suggests that CSF-1, together with its action on EGF, affects tumor cell ECM 
remodeling capabilities and likely plays a crucial role in overall tumor motility. These 
signals also imbue advanced remodeling capabilities to nearby macrophages that assist in 
the breakdown of the endothelial basement membrane.  
Another such pro-metastatic system affected by CSF-1 is the plasminogen 
activator (PA) system, which functions through the expression of a serine protease, 
urokinase-type plasminogen activator (uPA). Found to have clinical and prognostic value, 
“uPA is known to be involved in tumor angiogenesis and stromal remodeling…[and it is] 
localized in both stromal and malignant epithelial cells [and] the uPA receptor, uPAR, is 
mainly in…macrophage-like stromal cells, especially when these cells surround the 
invasive breast cancer” (Lin et al., 2002). CSF-1 influences uPA, which in turn influences 
macrophages, further supporting CSF-1 expression as an indicator of ECM remodeling 
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and eventual tumor metastasis. In addition, the PA system promotes vessel wall 
remodeling. 
For the next step of intravasation to occur, tumor cells must disrupt endothelial 
cell connections in order to enter the bloodstream. This process is known as 
transendothelial migration (TEM) (Reymond et al., 2013). TEM can be completed in one 
of two ways: (1) paracellular TEM, in which tumor cells pass between endothelial cells 
by disrupting cell-to-cell junctions, and (2) transcellular TEM, in which tumor cells move 
through endothelial cells, causing permanent damage. It has been demonstrated that the 
paracellular route is used almost exclusively by tumor cells in in vitro studies (Reymond 
et al., 2013).  
 
Figure 3. Model of tumor metastasis: invasion, intravasation, extravasation, and 
proliferation. Adapted from Reymond, d’Água, and Ridley (2013). 	  
Components related to intravasation include both VEGF and MenaINV, which 
have already been shown to contribute toward the overall invasive and metastatic 
processes. The ability to undergo paracellular TEM requires an interruption of tight 
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junctions between cells. Studies have found that the epithelial to mesenchymal transition 
promotes the dissolution of tight junctions so that cells can detach and become more 
motile (Mansel, 2007). The same mechanism by which tumor cells undergo this transition 
may occur with endothelial cells as well. In close proximity, the EMT-promoting factors 
may initiate the transition not only in tumor cells but also in nearby endothelial cells. 
Once tumor cells break through the endothelium, they must survive the shear stress of 
passing between cells, evade an immune response, and be of sufficiently small size to 
travel through vessels. Studies on animal models have shown that less than 0.01% of all 
cells that break away from the primary tumor develop into micrometastases (Reymond et 
al., 2013).  
In order to reach the next step in metastasis, tumor cells must undergo 
extravasation. Tumor cells in circulation first attach to the endothelial cell, a process that 
usually occurs in small capillaries. To do so, the tumor cell expresses particular ligands 
and receptors such as cadherins, selectins, and integrins. Selectins have been shown to be 
crucial in rolling adhesion followed by extravasation of leukocytes in the immune 
response. Although tumor cells have not yet been shown to extravasate in this manner, 
the mechanism may be similar. (Mansel, 2007) 
 Once extravasation has occurred, tumor cells lie dormant, die, or proliferate into a 
secondary tumor. Breast cancer as a primary tumor often metastasizes to the bone, brain, 
liver, and lungs (Mansel, 2007). The processes related to the proliferation of secondary 
tumors are beyond the scope of this study. 
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MetaSite BreastTM and MenaCalcTM Diagnostic Platforms 
MetaStat, Inc., located in Boston, Massachusetts, has developed an 
immunohistochemistry-based assay that quantifies metastatic structures. The MetaSite 
Breast™ test assesses the risk of metastasis based on the quantification of MetaSitesTM, 
the physical location of three distinct structures: a tumor-derived macrophage, a Mena 
protein-positive tumor cell, and a blood vessel. When these three structures are in direct 
apposition to one another, it is termed a tumor microenvironment of metastasis (TMEM). 
In a case-control study of 481 patients, TMEM density was shown to directly correlate 
with increased risk of developing metastatic cancer. To determine a MetaSiteTM score, 
automated microscopy is performed, and the three most TMEM-dense fields are used. 
The number of TMEMs in those three fields is summed for the MetaSiteTM score. Studies 
by Rohan et al. (2014) showed that TMEM density correlates with patient prognosis 
among ER+/HER2- patients. The MetaSite BreastTM test was run on the same cohort and 
results demonstrated that the test provides comparable and equivalent data. 
MetaSitesTM are quantified on a continuous scale with a score of 0 indicating a 
complete lack of TMEMs. Patients with a MetaSiteTM score of <12 have a relatively low 
risk of metastasis, patients with a MetaSiteTM score of 12-35 have an intermediate risk, 
and patients with a MetaSiteTM score >35 have a high risk. Univariate and multivariate 
analyses show that patient samples with 12 or more MetaSitesTM have a greatly increased 
risk of metastasis. Compared with the low-risk category, univariate analysis shows a 
3.24-fold greater risk for patients in the intermediate-risk category and a 3.42-fold greater 
risk for patients in the high-risk category.  These observations are independent of nodal 
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status, tumor size, and tumor grade in multivariate analysis. Although there is a 
significant difference between low risk and intermediate/high risk, the difference between 
intermediate and high is less obvious, and the difference in risk is less significant. These 
findings suggest the adoption of a 2-bin system of low risk and high risk, instead of the 3-
bin system currently in use with the MetaSiteTM score. The MetaSite Breast™ test is 
predictive for the following breast cancer molecular subtypes: ER+, HER2-, and both 
node-negative and node-positive. Current data do not support use with HER2+, triple 
negative, or ductal carcinoma in situ (DCIS). The MetaSite Breast™ test is slated for 
commercialization in 2016.  
While the MetaSite Breast™ test quantifies instances of TMEM structures, the 
MenaCalc™ test specifically quantifies Mena protein isoform expression. The 
quantification of varying levels of protective and invasive proteins can provide a more 
comprehensive understanding of a tumor and its propensity to metastasize. Through 
quantitative analysis of Mena isoforms, the difference between invasive and noninvasive 
quantities is used to estimate the total predisposition to tumor cell metastasis, or Menacalc 
(Mena calculated). This is a theoretical MenaINV quantity that is measured indirectly. 
Even though there are isoforms of Mena other than MenaINV and Mena11a, they are not 
well characterized in breast cancer. It has been found that “Menacalc was associated with 
decreased disease-specific survival independent of patient age, receptor status and tumor 
size…[and] Menacalc was prognostic for poor outcome in node-positive patients” (Forse 
et al., 2015). 
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The MenaCalcTM diagnostic test uses a pan-Mena IHC marker and a Mena11a 
IHC marker. The protein expression levels are quantified using indirect antibody-
mediated detection, automated fluorescence microscopy, and a robust image analysis 
algorithm to identify tumor cells and quantify fluorescence intensity of each marker 
within identified regions. The MenaCalc™ score is calculated by subtracting the Z-score 
of Mena11a from the Z-score of pan-Mena (Agarwal et al., 2012). MenaCalc™ scores lie 
on a continuous scale from -3 to +3. A MenaCalc™ score between -3 and -0.06 indicates 
a low risk of metastasis. However, a MenaCalc™ score between -0.06 and +3 is 
considered high risk and a patient with such a score has a 2.2-fold greater risk of 
developing metastatic breast cancer than low-risk patients (Forse et al., 2015). The 
MenaCalc™ test is predictive for all node-negative breast cancer subtypes. Current data 
do not support use with node-positive breast cancer or DCIS. The MenaCalc™ test 
underwent analytical validation in January 2016.  
The prognostic utility of the MetaSite Breast™ and MenaCalc™ tests is expected 
to increase through further development of their synergistic use to predict the risk of 
breast cancer metastasis. 
Specific Aims and Objectives 
 This study aims to address the development of the MenaCalc™ test to identify 
patients with a high risk of metastasis and to treat the breast cancer before it metastasizes. 
The application of quantitative immunofluorescence and protein quantification methods 
with the MenaCalc™ test, in conjunction with the MetaSite™ test for measuring TMEM 
density, will be used to identify patients who can most benefit from aggressive 
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therapeutic interventions. This application will also identify patients who can be spared 
from therapies such as chemotherapy because of the non-invasive nature of their breast 
cancer. Furthermore, the prognostic utility of using both MetaSite Breast™ and 
MenaCalc™ as a synergistic method of predicting tumor metastasis will be examined. 
These assessments can be used as tools to help inform physicians of specific metastatic 
risk and they have the potential to directly affect patient treatment and overall disease 
prognosis.  
 The specific aims of this study are: 
1. To explain the biology and physiology of metastasis. 
2. To explain the biology and physiology of breast cancer tumors and 
tumor cells as they relate to the MetaSite Breast™ and MenaCalc™ 
diagnostic tests. 
3. To describe the development and analytical validation of the 
MenaCalc™ assay and diagnostic test. 
4. To assess the synergistic use of both MetaSite Breast™ and 
MenaCalc™ tests to further the understanding of individual patient 
cases. 
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METHODS 
Multiplexed Immunofluorescence Staining 
The formalin-fixed, paraffin-embedded (FFPE) tissue samples were baked in a 
60°C oven overnight for 12-16 hours. The slides then underwent three treatments of 
Xylenes (Fisher Scientific, Pittsburgh, Pennsylvania, USA) for 5 minutes each, using a 
fresh stock of Xylenes each time. The slides were soaked in 3 baths of 100% Reagent 
Alcohol (Ethanol) (Fisher Scientific) for 5 minutes each, again using a fresh stock each 
time. The slides were transferred to an ethanol gradient of 95% ethanol, 90% ethanol, and 
80% ethanol for 1 minute each. The slides were then soaked in deionized water for 5 
minutes. Antigen retrieval was performed using a NxGEN Decloaker (Biocare Medical, 
Concord, California, USA) and DIVA Decloaker RTU (Ready-to-Use) (Biocare Medical; 
pH 6.2) antigen retrieval solution at 95°C for 40 minutes. After antigen retrieval and 
cooling, the slides were transferred to a Tris-buffered saline plus Tween (TBST) solution 
(ScyTeck Logan, Utah, USA; pH 7.4).  
 The slides were loaded into a LabVision Autostainer 360-2D (Thermo Scientific, 
Waltham, Massachusetts, USA), and the MenaCalcTM autostainer protocol (steps 1-10) 
was run at room temperature. The protocol consisted of the following steps:  
1. Bloxall Endogenous Peroxidase and Alkaline Phosphatase Blocking Solution 
(Vector Labs, Peterborough, UK) was applied for 10 minutes followed by 3 TBST 
rinses. 
2. Normal Horse Serum (Vector Labs; 2.5%) was applied for 20 minutes followed 
by 3 TBST rinses and a 5-minute TBST soak.  
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3. A cocktail of 1:20,000 pan-Mena (anti-pan-Mena mouse monoclonal antibody; 
0.1 µg/mL) (Massachusetts Institute of Technology, Cambridge, Massachusetts, 
USA) and 1:300 Mena11a (anti-Mena11a rabbit polyclonal antibody; 0.3 µg/mL) 
(Massachusetts Institute of Technology) was diluted in DaVinci Green Diluent 
(Biocare Medical) and applied for 30 minutes followed by 3 TBST rinses and a 5-
minute TBST soak. 
4. ImmPRESSTM HRP Anti-Mouse (Vector Labs) secondary antibody and Tris-
buffered saline (TBS) (Fisher Scientific; pH 7.4) (1:1) were applied for 30 
minutes followed by 3 TBST rinses and a 5-minute TBST soak. 
5. TSATM Kit #40, with HRP-Goat Anti-Mouse IgG and Alexa Fluor® 555 
Tyramide with amplification buffer (1:100) (Life Technologies, Carlsbad, CA, 
USA), was applied for 10 minutes followed by 3 TBST rinses. 
6. Benzoic acid hydrazide solution (Benzoylhydrazine 98%; Fisher Scientific) was 
applied for 8 minutes followed by a TBST rinse, and a second benzoic acid 
hydrazide solution was applied for 7 minutes followed by 3 TBST rinses. 
7. ImmPRESSTM HRP Anti-Rabbit (Vector Labs) secondary antibody and TBS (1:1) 
were applied for 30 minutes followed by 3 TBST rinses and a 5-minute TBST 
soak. 
8. TSATM Reagent, Alexa Fluor® 647 Tyramide, and amplification buffer (1:100) 
(Life Technologies) were applied for 10 minutes followed by 3 TBST rinses. 
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9. Anti-Pan Cytokeratin (AE1/AE3) Alexa Fluor® 488 (Life Technologies) was 
diluted in Da Vinci Green Diluent (1:100) (Biocare Medical) and applied for 15 
minutes followed by 3 TBST rinses. 
10. DAPI FluoroPureTM (Fisher Scientific) was diluted in deionized water (1:5,000) 
and applied for 5 minutes followed by 2 TBST rinses.  
 
 After completion of the autostainer program, the slides were coverslipped using 
ProLong Gold® Antifade Mountant (Life Technologies). The slides were then incubated 
at 37 °C for 30 minutes followed by incubation at 60 °C for 30 minutes. 	  
Image Acquisition 
 Slide image acquisition was run overnight using a Vectra 2 Automated Slide 
Imaging System (Perkin Elmer, Hopkinton, Massachusetts, USA). The automated 
microscope first acquired monochrome 4x images to identify regions of tissue. With a 
map of the tissue, images were taken with the DAPI and FITC filter cubes to visualize 
DAPI and cytokeratin, respectively, so that the algorithm could identify areas that 
contained tumor. The algorithm ranked each field by DAPI and cytokeratin pixels. A 
minimum threshold level of 5% was required with regard to DAPI and cytokeratin-
positive epithelial cells per image. The algorithm then identified the densest fields of 
view and acquired those images, up to 30 per slide, at 20x magnification. Examples of 4x 
and 20x fields of view for both MenaCalcTM and MetaSite BreastTM are shown in Figure 
4. 
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Figure 4. MenaCalcTM and MetaSite BreastTM tissue staining. Top, MenaCalcTM 
imaging at 4x and 20x (inset); bottom, MetaSite BreastTM imaging at 4x and 20x (inset). 	  
Fluorescent dyes were chosen which provided both a clear and sufficient signal 
and minimized channel bleed-through. Fluorescent dyes are based on fluorophores that 
excite at a given wavelength and then emit at a higher wavelength; the difference 
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between these wavelengths is called a Stokes shift. A greater Stokes shift allows for a 
greater ability to detect emission spectra against background noise and background 
fluorescence. After analysis of excitation and emission spectra overlap between different 
fluorescent dyes, dyes that excite at 405 nm (DAPI), 488 nm (Alexa Fluor® 488), 555 
nm (Alexa Fluor® 555), and 647 nm (Alexa Fluor® 647) were chosen for their ability to 
be used together in a multiplexed assay. Figure 5 shows the excitation and emission 
spectra and the Stokes shift of the fluorescent dyes used in this assay. 
 
Figure 5. Fluorescent dye excitation and emission spectra. For each of the four 
fluorescent dyes used in the MenaCalcTM assay, excitation is shown by a dashed line and 
emission is shown by a solid line. This image illustrates that the emitted signals vary and 
can produce images with well-differentiated biomarkers. Image adapted from 
Fluorescence SpectraViewer | Thermo Fisher Scientific (n.d.). 
 
Tissue microarray (TMA) control slides were used to identify optimal exposure 
times for each fluorescence channel in each batch of slides. DAPI, FITC, CY3, and CY5 
filter cubes were selected to allow only certain wavelengths of light to pass through and 
permit visualization of individual fluorescent dyes. Selective filtering was necessary for 
spectral unmixing later in the imaging process. The fluorescent dye DAPI (excites at 405 
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nm) was visualized using the DAPI filter cube, cytokeratin (488 nm) with the FITC filter 
cube, pan-Mena (555 nm) with the CY3 filter cube, and Mena11a (647 nm) with the CY5 
filter cube. For each channel, the exposure time was determined using the brightest core 
of a TMA cell line control and was considered the theoretical maximum brightness to 
avoid both overexposure and underexposure of the images. Setting the exposure 
according to the brightest spot avoided overexposure and blowout of bright spots (often 
from autofluorescence) and allowed other areas of the image to receive sufficient time to 
produce a robust image.  
 
Image Analysis 
  A tumor mask was applied using inForm software, version 2.2.1 (PerkinElmer), 
with a custom algorithm that detected cytokeratin-positive tumor cells. The algorithm 
was developed by using the trainable tissue segmentation tool: the software operator 
manually indicated tumor, stroma, and other areas, and the algorithm learned by example. 
Both typical and atypical areas of tissue were examined so the algorithm could develop a 
wide repertoire of image data. With more use, the pattern recognition algorithm 
consistently and accurately recognized tumor and non-tumor tissue through morphology 
and biomarker expression data. 
 The image analysis algorithm identified epithelium by cytokeratin fluorescence 
with Alexa Fluor® 488 and a DAPI nuclear counterstain. In tumor cells, pan-Mena and 
Mena11a were visualized with Alexa Fluor® 555 Tyramide and Alexa Fluor® 647 
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Tyramide, respectively. Once the algorithm was established, it was used for the 
acquisition and analysis of all images. 
InForm software created unmixed images by separating the composite image into 
four pure fluorescence channel images created by the four filter cubes (DAPI, FITC, 
CY3, and CY5), as shown in Figure 6. Cells were automatically detected and membranes 
were delineated. Intensity per unit time was used to quantify a fluorescence intensity 
value per pixel. Cell-level mean and total pan-Mena and Mena11a values for each 20x 
image were exported.  
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Figure 6. Breast cancer whole tissue slides: spectrally unmixed images, tumor 
masking image, and whole slide image. (A) 20x unmixed Mena11a; (B) 20x unmixed 
pan-Mena; (C) 20x unmixed cytokeratin and DAPI; (D) 20x tumor mask application; (E) 
20x composite image; (F) 4x overall tumor image. 
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Statistical Analysis 
Data were processed in SPSS Statistics, version 22.0 (IBM, Chicago, Illinois, 
USA), and a MenaCalc™ score was calculated for each patient slide. Based on the data 
from the fields of view of a single slide, total pixel values were divided by pixel values 
contained within the cytoplasm to yield a normalized score. This calculation was also 
performed at the cell level so that the protective versus non-protective expression of 
Mena isoforms was determined on a cell-by-cell basis. This cell-level calculation 
provided for a more complete view of metastasis risk by taking into consideration the 
heterogeneity of a given tissue sample. MenaCalc™ scores were obtained by subtracting 
the Mena11a Z-score from the pan-Mena Z-score, resulting in the Z-score of the cells 
with the potential to express MenaINV, the pro-metastatic Mena isoform. Scores were 
binned into three categories of low, medium, and high risk of metastasis based on tertiles 
(scores of ≤-0.09, -0.09 to -0.01, and ≥-0.01, respectively). 
During development of the MenaCalc™ assay, Pearson’s correlation coefficient 
(R) was used as a measure of reproducibility for overall assay performance (day-to-day) 
and a measure of analytical precision for imaging and scoring (run-to-run). Benchmark 
goals for day-to-day reproducibility were as follows: Pearson’s R > 0.80; slope 0.8-1.2; 
and % coefficient of variation (CV) < 20%. Benchmark goals for run-to-run precision 
were as follows: Pearson’s R > 0.90; slope 0.9-1.1; and % CV < 10%. In addition, 
Spearman’s rho (ρ) was used to determine any association between MetaSite Breast™ 
and MenaCalc™ tests.  
	  28 
RESULTS 
Assay Development 
Developing an assay for commercial use requires ideal conditions at numerous 
points throughout the assay itself. The antibodies must be chosen for the biomarkers of 
interest and a precise concentration for each antibody must be determined. Any potential 
sources of deviation must be controlled and regulated as much as possible to ensure 
staining consistency across various staining batches. Lastly, as a commercial product, 
feasibility due to time restrictions must also be taken into account. 
During assay development, titration experiments were performed to establish 
optimal working dilutions for the primary antibodies, pan-Mena and Mena11a. The most 
effective dilution was selected as the highest signal-to-noise ratio that did not exceed the 
upper or lower limit of detection for the imaging system. A high signal-to-noise ratio 
allowed an optimal dynamic range for each of the pertinent biomarkers so that both low-
expressing and high-expressing cells captured a quantity of antibody sufficient to produce 
a clear fluorescent signal. 
The titer optimization experiment was begun by individually diluting pan-Mena 
and Mena11a at the following concentrations: 3.3 µg/mL, 1.0 µg/mL 0.33 µg/mL, 0.1 
µg/mL, 0.03 µg/mL, and 0.01 µg/mL. In addition, control slides for pan-Mena and 
Mena11a were used in which each was stained without the respective antibody. The mean 
fluorescence intensity values of the mean pan-Mena and the mean Mena11a were plotted 
for each of the antibody dilutions as shown in Figure 7.  
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Figure 7. Pan-Mena and Mena11a titer optimization. The plots show the mean 
fluorescence intensity values of the mean titer concentrations for (A) pan-Mena and (B) 
Mena11a. The low average designation was obtained by calculating the mean of the low 
fluorescence intensities among cells for a given dilution; the high average designation 
was obtained by calculating the mean of the high fluorescence intensities among cells. A 
high ratio indicates dynamic range optimization and is the ideal concentration at which 
the antibody should be used. NP = No primary antibody. 
A 
B 
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The high average and low average values, as plotted in Figure 7, were obtained by 
taking the brightest 20 images and the dimmest 20 images and averaging the values. This 
provides an average range of values that the automated microscope will be required to 
detect. The ratio of high average to low average indicates the relative intensity of the 
fluorescent stain at a given dilution. The Mena11a data showed a strong peak at 3.3 
µg/mL, indicating the optimal dilution for Mena11a. Further titer experiments were 
performed for pan-Mena because of the peaks at 0.33 µg/mL and 0.03 µg/mL and the 
significant decrease in the mean value of the pan-Mena mean at 0.1 µg/mL. These peaks 
suggested that the optimal pan-Mena dilution was unclear and possibly due to inadequate 
staining at 0.1 µg/mL. The pan-Mena titer was performed again using dilutions at 0.1 
µg/mL, 0.067 µg/mL, 0.05 µg/mL, and 0.03 µg/mL, and a control slide was stained 
without the pan-Mena primary antibody.  
The repeat titer optimization experiment (graph not shown) displayed sufficient 
staining throughout the slides. Dilutions of 0.1	  μg/mL, 0.067	  μg/mL, and 0.05	  μg/mL 
had adequately high ratios that indicated suitability for use in the assay. However, a 
dilution of 0.05	  μg/mL was chosen based on the exposure times necessary to capture 
both the lower pan-Mena expressing cells and the higher pan-Mena expressing cells. 
With this dilution, the exposure times were neither excessively high, indicating lower 
concentrations of pan-Mena, nor excessively low, indicating higher concentrations of 
pan-Mena. It was important to consider exposure times and to find a dilution that did not 
push the limits of the imaging system.  
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Collaborations with researchers at Albert Einstein College of Medicine (Bronx, 
New York, New York, USA) and at Massachusetts Institute of Technology (Cambridge, 
Massachusetts, USA) resulted in the assay being modified so it would be viable as a 
commercially reproducible product. In the original assay, the anti-mouse IgG horseradish 
peroxidase (HRP) was quenched by heating in a microwave oven. Temperature and 
pressure were not accurately controlled or recorded. Furthermore, when staining various 
quantities of slides, the internal temperature varied even with consistent heating duration. 
An alternate method to ensure regulated and consistent HRP quenching across all slides 
and all staining batches was adopted using a benzoic acid hydrazide solution that was 
applied during the standard staining procedure. The addition of this solution to the assay 
program allowed for staining consistency because it was applied in the same manner as 
the other staining reagents with the autostainer machine.    
In the development of a commercial product, the duration of the whole process 
must also be taken into account. The initially developed assay had a the staining process 
that took approximately 8 hours, with nearly 50 minutes added to the beginning for 
preparations and 80 minutes added to the end for coverslipping and oven drying. The 
process, at more than 10 hours, well exceeded a normal shift and image acquisition could 
not begin until the following business day. This time restraint impeded the goal of 
staining and beginning image acquisition on the same day to increase throughput 
workflow. Consequently, the staining process was modified until the assay showed both 
consistent and accurate results with a significantly decreased run duration (data not 
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shown). The final staining duration took approximately 7 hours with a complete start-to-
finish time of just over 9 hours. 
 
MenaCalc™ Analytical Validation 
MenaCalc™ underwent CLIA-compliant analytical validation in January 2016. A 
pathologist verified all tissue samples for diagnostic quality and validated the quality of 
individual images used for MenaCalc™ scoring. Of 35 tissue samples that were stained, 
6 were rejected for poor tissue quality and 1 was rejected because of image quality and 
insufficient fields of view. For the remaining 28 whole tissue samples (N = 993,603 
cells), analysis was performed and the assay demonstrated high performance and 
precision.  
Pearson’s R was used as a measure of reproducibility because it calculates the 
linear correlation between two variables. Values range from -1, indicating a strong 
negative correlation, to +1, indicating a strong positive correlation; a value of 0 indicates 
no correlation. The slope was used to assess how one variable changes per unit change of 
the other variable; specifically, the slope was used to determine if pan-Mena and 
Mena11a change at the same rate. Mena11a, as a Mena isoform, was included in the pan-
Mena staining and a slope of approximately 1 was expected, indicating equivalence of 
measurements with regard to staining and imaging of pan-Mena and Mena11a. 
Day-to-day reproducibility of an assay is important because of the heterogeneity 
of tissue. Day-to-day data for the MenaCalcTM assay are summarized in Table 2. The 
percent coefficient of variation (%CV) was 2.31%, meeting the benchmark of < 20%. 
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The Pearson’s R was 0.879 and 0.853 for Day 1 vs. Day 2 and for Day 1 vs. Day 3, 
respectively. Based on these data, the correlation was very strong between day-to-day 
runs. The slopes for Day 1 vs. Day 2 and for Day 1 vs. Day 3 were 0.985 and 0.982, 
respectively. These slopes indicated a nearly perfect 1:1 increase with regard to the 
MenaCalcTM score comparisons between staining days.  
Primary Benchmark: Pearson’s R > 0.80; Slope 0.8-1.2 
Secondary Benchmark: %CV < 20% 
 Day 1 vs. Day 2 Day 1 vs. Day 3  
 Pearson’s R Slope Pearson’s R Slope %CV 
(Range) 
Pan-Mena 0.905 1.037 0.950 1.005 2.75  
(0.26-7.44) 
Mena11a 0.948 1.034 0.950 0.990 3.60  
(0.68-7.06) 
MenaCalc™ 0.879 0.985 0.853 0.982 2.31 
(0.07-6.95) 
Table 2. Data summary for day-to-day reproducibility of the MenaCalc™ assay. 
Reproducibility of pan-Mena and Mena11a signals were also included to ensure 
consistent staining results. CV = coefficient of variation; N = 28.  	  
 Run-to-run reproducibility is crucial to ensure precision in imaging and in scoring 
tissue samples. Run-to-run data for the MenaCalcTM assay are summarized in Table 3.  
The run-to-run analysis yielded a %CV of 0.45%, meeting the benchmark of < 10%. As 
expected with the run-to-run analysis, Pearson’s R and slope values were even more 
precise than the day-to-day values. With Pearson’s R of 0.999 and 0.994 for Day 1 vs. 
Day 2 and for Day 1 vs. Day 3, respectively, a nearly perfect correlation. This contributed 
further to the confidence in the precision of the MenaCalcTM assay. Slope values of 0.999 
and 0.999 for Day 1 vs. Day 2 and for Day 1 vs. Day 3, respectively, indicated that the 
imaging system as precisely quantifying the pan-Mena and Mena11a fluorescent signals. 
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Primary Benchmark: Pearson’s R > 0.90; Slope 0.9-1.1 
Secondary Benchmark: %CV < 10% 
 Day 1 vs. Day 2 Day 1 vs. Day 3  
 Pearson’s R Slope Pearson’s R Slope %CV 
(Range) 
Pan-Mena 0.998 1.001 0.995 1.004 0.46 
(0.05-1.33) 
Mena11a 0.999 0.997 0.997 0.997 0.41 
(0.06-1.31) 
MenaCalc™ 0.999 0.999 0.994 0.999 0.45 
(0.02-2.32) 
Table 3. Data summary for run-to-run reproducibility of the MenaCalc™ assay. 
Reproducibility of pan-Mena and Mena11a signals were also included to ensure 
consistent imaging and scoring results. CV = coefficient of variation; N = 28. 	  
All benchmarks for the MenaCalcTM assay were met with respect to Pearson’s R, 
slope, and % CV across pan-Mena, Mena11a, and overall MenaCalc™ scores. The 
MenaCalc™ assay passed analytical validation under CLIA-compliance, demonstrating 
that the assay has a high degree of precision and a very strong day-to-day reproducibility. 
Z-scores for pan-Mena and Mena11a scores for individual cells across all samples 
(n=35) were calculated.  A MenaCalc™ score was then calculated for each cell and 
subsequently divided into tertiles: low (<-0.09), intermediate (-0.09 to -0.01), and high 
(>-0.01) groups. The total range of MenaCalc™ scores was -21.84 to 13.54.  As shown in 
the XY scatter plot between Mena11a and pan-Mena Z-scores (Figure 8), cells with high 
MenaCalcTM had a range of Mena expression from low to high, which indicated the 
independence of MenaCalcTM from total Mena expression. 
Of note to this study, basic clinical data were available for the samples used in the 
analytical validation. Analysis of MenaCalc™ scores indicated that there was no 
significant association with molecular subtype, node status, or tumor stage or grade. 
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Further analysis is underway examining the effects of specific tumor cell heterogeneity 
with respect to clinical features. 
 
 
Figure 8. Individual cell MenaCalc™ values (Z-scores) based on low, intermediate, 
and high designations. MenaCalc™ demonstrates the relationship between total pan-
Mena values and Mena11a. MenaCalc™ scores are independent of pan-Mena expression. 
Results were log-transformed to remove any negative values for data analysis.  	  
MetaSite Breast™ and MenaCalc™  
 The synergistic capabilities of MetaSite Breast™ and MenaCalc™ were 
examined by staining a cohort of serial sections for each test. All samples were evaluated 
by a pathologist for tissue quality and all were assessed for staining and imaging quality 
against control slides. The MetaSite™ and MenaCalc™ scores clustered into three main 
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categories: MetaSite Breast™ low and MenaCalc™ low; MetaSite™ low and 
MenaCalc™ high; and MetaSite™ high and MenaCalc™ high. Notably, cases with a 
high MetaSite BreastTM score (high TMEM) and a low MenaCalcTM score were absent, 
indicating the possible need of high MenaCalcTM for TMEM formation. 
Figure 9. Relationship of MetaSite Breast™ score to MenaCalc™ score. Clusters of 
statistical significance include MetaSite™ low and MenaCalc™ low (blue), MetaSite™ 
low and MenaCalc™ high (red), and MetaSite™ high and MenaCalc™ high (green). 
There are no significant clusters of a high MetaSite™ score and a low MenaCalc™ score. 
Spearman’s rho (ρ) = 0.22; P=0.27; N = 28. 
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Regions of High MenaCalcTM Scores 
Cell-level analysis was performed on individual fields of view to determine how 
MenaCalcTM scores related to physical tissue structures (i.e., invasive tumor). InForm 
software algorithms identified and segmented cells individually and, after segmentation, 
MenaCalcTM was performed on every individual cell in a field of view. Binned 
MenaCalcTM scores (based on low, intermediate, and high tertiles) were then plotted on 
an XY plane as shown in Figure 10. This allowed for visualization of the MenaCalcTM 
scores on a cell-by-cell basis relative to the cell’s physical location in the tissue sample.  
The percentage of MenaCalcTM scores that were designated as high was 
calculated for each tissue sample. One example (Figure 10C) showed a very large 
proportion of high MenaCalcTM scores (97.4% of cells in the image), which suggested 
highly invasive tumor cells in the area. Another example (Figure 10A) indicated only 
6.6% of tumor cells with a high MenaCalcTM score. This image demonstrated clearly 
defined areas with non-invasive tumor cells and areas with some invasive tumor cells. An 
example with an intermediate amount of high MenaCalcTM scores (30.1%) was also 
found (Figure 10B). This image showed both invasive and non-invasive tumor cells. 
These results provided evidence that high MenaCalcTM scores correlated with an invasive 
phenotype.  
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Figure 10. Binned MenaCalcTM scores for analytical validation. MenaCalcTM scores 
are calculated for each cell in the field of view and binned into low (green), intermediate 
(blue), and high (red) tertiles. Each MenaCalcTM score is plotted on an XY plane to show 
its location in the image and the percentage of high (red) scores is determined for each 
image. Examples of the plots of the binned MenaCalcTM scores and the associated images 
are shown for 6.6% MenaCalcTM high scores (A), 30.1% MenaCalcTM high scores (B), 
and 97.4% MenaCalcTM high scores (C). Magnification = 20x. 
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DISCUSSION 
Analytical Validation 
Current biomarker-based tests for breast cancer, such as those for ER/PR and 
HER2 status, vary widely in their day-to-day and run-to-run reproducibility. The same 
sample can receive different results if tested at different laboratories or even if tested 
twice at the same laboratory. The tests to determine ER/PR and HER2 status are used to 
help physicians determine the best course of treatment for a given patient. However, 
physicians may not be completely informed about the characteristics of a given breast 
cancer case because of the reproducibility flaws of these tests. In such a situation, the 
patient may not receive the most personalized care or the best course of treatment. 
Moreover, with varying results, physicians may question the clinical utility of a given test 
and instead may use their own clinical experience in deciding the course of treatment. In 
developing the MenaCalcTM test, the goal was to create a highly precise and reproducible 
assay so that a physician can make informed decisions about treatment based on accurate 
data.   
The day-to-day and run-to-run benchmarks that were set for the MenaCalcTM 
analytical validation were well exceeded. On a day-to-day basis across 3 staining days, 
the slope comparing the MenaCalcTM of Day 1 and Day 2 was 0.985 and the slope 
comparing Day 1 and Day 3 was 0.982. On a run-to-run basis, the slopes were even more 
precise at 0.999 for both comparisons. Even though there are many variables at work 
including staining reagents, highly sensitive fluorophores, ambient light and imaging, 
exposure times and autofluorescence, the MenaCalcTM assay is highly precise and 
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reproducible. With analytical validation performed under CLIA guidelines and standard 
operating procedures, the MenaCalcTM assay is slated for cohort-based studies and 
commercialization in the near future.  
 
MetaSite Breast™ and MenaCalc™ Synergy 
The MetaSite Breast™ and MenaCalc™ diagnostic platforms were developed to 
assess risk of metastasis based on different aspects of the metastatic cascade. Each test 
can provide specific insight into individual breast tumor biology. 
 The Menacalc method of analyzing breast cancer had been previously verified as 
an independent prognostic marker in breast cancer (Agarwal et al., 2012; Forse et al., 
2015). However, developing MenaCalc™, a high-throughput commercial assay, required 
precision and performance as a foundation for clinical utility. During analytical validation 
of the MenaCalc™ assay and through preliminary investigations into its synergy with the 
MetaSite Breast™ diagnostic platform, it was discovered that using a combination of the 
two tests yields additional tumor-specific information. Of particular interest is the 
clustering of three score-combination patterns: MetaSite™ low and MenaCalc™ low; 
MetaSite™ low and MenaCalc™ high; and MetaSite™ high and MenaCalc™ high. 
These clusters may indicate various subpopulations of breast cancer cases. 
 The combination of a low MetaSite™ score and a low MenaCalc™ score may 
signify non-invasive breast cancer. With a low MetaSite™ score, there is a low density of 
TMEM sites, suggesting that the tumor has somewhat limited capability or opportunity to 
metastasize. A low MenaCalc™ score indicates that the tumor cells probably do not have 
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sufficient MenaINV expression at the molecular level to be able to metastasize. Tumor 
cells are minimally invasive and the tumor cell/macrophage/endothelial cell group is not 
interacting in a way that promotes metastasis at this time. As a result, this score 
combination of a low MetaSiteTM score and a low MenaCalcTM score may indicate the 
potential for a good prognosis because metastasis is not possible. 
The second combination of a low MetaSite™ score and a high MenaCalc™ score 
may denote early stages of metastatic cancer. Although a low MetaSiteTM score implies 
few instances of TMEMs, a high MenaCalc™ score signifies expression of MenaINV at a 
level greater than that of the protective Mena11a. These tumor cells are progressively 
acquiring or have already acquired the ability to invade surrounding areas. This can be a 
preliminary stage of the positive feedback loop between macrophages and invasive tumor 
cells. The tumor, though invasive, has not yet influenced the microenvironment to 
develop significant numbers of TMEMs. With tumor resection and aggressive treatment, 
a patient with this set of combined scores may have an intermediate to good prognosis.  
The third combination of a high MetaSite™ score and a high MenaCalc™ score 
may indicate that the tumor is already metastatic. There are a high number of TMEMs 
and the tumor has invasive capabilities. With both the ability and the opportunity to 
metastasize, aggressive treatment may be beneficial in providing the best possible 
prognosis. 
One combination that was not observed is a high MetaSite™ score with a low 
MenaCalc™ score. A combination score of this nature represents a patient with a 
significant quantity of TMEMs together with tumor cells that do not possess invasive 
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capabilities. It seems biologically unlikely, or perhaps impossible, to have both non-
invasive tumor cells and TMEMs at the same time. A TMEM, formed by any means 
other than the unlikely and purely random apposition of a Mena-expressing tumor cell, a 
macrophage, and an endothelial cell, does not exist without the signals propagated by an 
invasive tumor cell. Based on the studies that indicate both MetaSite Breast™ and 
MenaCalc™ tests are prognostic indicators of metastasis, this score combination is not 
possible.  
The treatment and prognostic outcomes associated with the combination scores of 
the MetaSite BreastTM and MenaCalcTM tests are purely speculative. It is important to 
note that these diagnostic platforms quantify a risk and do not in any way indicate a 
specific course of treatment or prognosis. It is up to the clinician to decide the best course 
of treatment for an individual patient and to make a prognostic determination only after 
reviewing a complete patient record. 
Both MetaSite BreastTM and MenaCalcTM are undergoing trials with the ECOG 
2197 cohort that will provide level 1B evidence. The aims of these trials are to assess the 
predictive nature of the tests and to assess how MetaSite BreastTM and MenaCalcTM can 
be used together to gather more data and to provide a more robust and complete 
understanding of a given breast cancer case. Future studies for MenaCalcTM include work 
with the Calgary Tamoxifen Breast Cancer Cohort (Tom Baker Cancer Centre, Calgary, 
Alberta, Canada) and the Kaiser Permanente Northwest (KPNW) Tumor Registry Cohort 
(Kaiser Permanente Northwest, Portland, Oregon, USA).  
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Conclusion and Forward-Looking Statements 
 The results of this study show that the MenaCalcTM test is a precise and 
reproducible assay that can be used in conjunction with the MetaSite Breast™ test for 
increased clinical utility. 
The next area of exploration will be in developing an assay that directly uses a 
MenaINV antibody to quantify invasive tumor cells. This will be beneficial because it 
simplifies the assay and provides a direct quantification of MenaINV levels instead of an 
indirect, calculated quantification using pan-Mena and Mena11a. Other minor Mena 
isoforms will be investigated for any pro-metastatic indications.  
In addition, it has been shown through various studies (Gertler & Condeelis, 
2011) that the principles underlying both the MetaSite Breast™ and the MenaCalc™ 
tests, namely the analysis of differential Mena expression, can be used to investigate 
metastasis risk of other cancers, including pancreatic, colon, and cervical carcinomas. 
Consequently, the future development of these tests may provide a similar clinical utility 
in treating various types of cancers. 
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